A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jun 2018
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms ELIGANT
- Sponsors Astellas Pharma
- 29 May 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2018 Planned number of patients changed from 345 to 107.
- 22 Mar 2018 Planned End Date changed from 1 Aug 2020 to 1 Jan 2020.